TSO3 submits documentation to support export of new sterilizer to the United
States and Europe
Stock symbol:TSX: TOS Outstanding shares: 47,863,402
The Company announced receiving Health
"We are extremely pleased that we have met the milestones of regulatory submission in multiple markets that we set out for ourselves and communicated to our investors during the year", stated Mr. R.M. (Ric) Rumble, President and CEO of TSO3. "Our new total solution in sterilization comes at a time when customers are seeking alternatives for their low temperature sterilization needs", concluded
On
About TSO3
TSO3 was founded in June of 1998, supported by a patented and unique technology for the sterilization of medical devices. This process uses ozone as the sterilizing agent and has been designed to allow the sterilization of heat and moisture-sensitive medical devices in healthcare settings.
The STERIZONE(R) Sterilization Process sterilizes large loads of medical devices quickly, cost-effectively, safely and in an eco-friendly way. This is in contrast to traditional gaseous low temperature sterilization methods which rely on toxic chemistry and require lengthy sterilization cycle times, or newer competitive oxidizing sterilizers which are costly to operate and limited in capability due to their load restrictions.
TSO3's first product, the STERIZONE(R) 125L Sterilizer has received clearance for commercialization from both Health
For more information about TSO3, visit the Company's Web site at www.tso3.com
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
For further information: Caroline Côté, Director, Corporate Communications and IR, Cell Phone (418) 576-2333, [email protected]; Source: TSO3 Inc.
Share this article